NCT03547895View on ClinicalTrials.gov

Management of Decompensated HCV Cirrhotic Patients

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

May 24, 2016

Study Completion Date

June 24, 2018

Conditions
Decompensated Cirrhosis
Interventions
DRUG

Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)

sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months

DRUG

vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion

symptomatic therapy for liver support, control of ascites and bleeding tendency.

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT03547895 - Management of Decompensated HCV Cirrhotic Patients | Biotech Hunter | Biotech Hunter